THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling

Gastric adenocarcinomas can be divided into two major histological types, the diffuse and intestinal type (Laurén classification). Since they diverge in many clinical and molecular characteristics, it is widely accepted that they represent distinct disease entities that may benefit from different therapeutic approaches. Gene expression profiling studies have identified numerous genes that are differentially expressed between them. However, none of these studies covered the whole transcriptome and the published gene lists reveal little overlap, raising the need for further, more comprehensive analyses. Here, we present the first transcriptome-wide expression profiling study comparing the two types (diffuse n=19, intestinal n=24), which identified >1000 genes that are differentially expressed. Among them, thrombospondin 4 (THBS4) showed the strongest correlation to histological type, with vast overexpression in the diffuse type. Quantitative real-time PCR validated this strong overexpression and revealed that intestinal tumors generally lack THBS4 expression. Immunohistochemistry demonstrated THBS4 overexpression on the protein level (n=10) and localized THBS4 to the stromal aspect. Its expression was primarily observed within the extracellular matrix surrounding the tumor cells, with the highest intensities found in regions of high tumor cell density and invasion. Intestinal tumors and matched non-neoplastic gastric epithelium and stroma did not feature any relevant THBS4 expression in a preliminary selection of analyzed cases (n=5). Immunohistochemical colocalization and in vitro studies revealed that THBS4 is expressed and secreted by cancer-associated fibroblasts. Furthermore, we show that THBS4 transcription in fibroblasts is stimulated by tumor cells. This study is the first to identify THBS4 as a powerful marker for diffuse-type gastric adenocarcinomas and to provide an initial characterization of its expression in the course of this disease.

[1]  J. Siewert,et al.  Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. , 1998, Annals of surgery.

[2]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[3]  J. Lawler,et al.  Characterization of Human Thrombospondin-4 (*) , 1995, The Journal of Biological Chemistry.

[4]  C. Bonferroni Il calcolo delle assicurazioni su gruppi di teste , 1935 .

[5]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[6]  N. Wright Morson and Dawson’s Gastrointestinal Pathology, 4th edn , 2005 .

[7]  John R. Mackey,et al.  Gastric Adenocarcinoma: Review and Considerations for Future Directions , 2005, Annals of surgery.

[8]  Yusuke Nakamura,et al.  Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray , 2004, Oncogene.

[9]  O. Debeir,et al.  Exploring the Distinctive Biological Characteristics of Pilocytic and Low-Grade Diffuse Astrocytomas Using Microarray Gene Expression Profiles , 2006, Journal of neuropathology and experimental neurology.

[10]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[11]  Li‐yu Lee,et al.  Identification of differential gene expression between intestinal and diffuse gastric cancer using cDNA microarray. , 2006, Oncology reports.

[12]  H. Höfler,et al.  Gastric adenocarcinoma: pathomorphology and molecular pathology , 2001, Journal of Cancer Research and Clinical Oncology.

[13]  R. Takimoto,et al.  Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. , 1994, British Journal of Cancer.

[14]  Nils Blüthgen,et al.  Biological profiling of gene groups utilizing Gene Ontology. , 2004, Genome informatics. International Conference on Genome Informatics.

[15]  G. Gabbiani,et al.  Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction , 1971, Experientia.

[16]  L. Matrisian,et al.  Epithelial-stromal interactions and tumor progression: meeting summary and future directions. , 2001, Cancer research.

[17]  B. Gibbs,et al.  The C-terminal peptide of thrombospondin-4 stimulates erythroid cell proliferation. , 2004, Biochemical and biophysical research communications.

[18]  Ximing J. Yang,et al.  Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implications. , 2004, Urology.

[19]  Hong Nguyen,et al.  Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. , 2004, Archives of pathology & laboratory medicine.

[20]  John D. Storey A direct approach to false discovery rates , 2002 .

[21]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[22]  M. Vieth,et al.  Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Goodison,et al.  CD44 cell adhesion molecules. , 1999, Molecular pathology : MP.

[24]  Jane Fridlyand,et al.  Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. , 2003, Cancer research.

[25]  Shuichi Tsutsumi,et al.  Global gene expression analysis of gastric cancer by oligonucleotide microarrays. , 2002, Cancer research.

[26]  竹村 哲 Novel models for human scirrhous gastric carcinoma in vivo , 2005 .

[27]  T. Nevalainen,et al.  Epidemiology of intestinal and diffuse types of gastric carcinoma a time‐trend study in finland with comparison between studies from high‐ and low‐risk areas , 1993, Cancer.

[28]  N. Agnantis,et al.  Gastric Cancer: Introduction, Pathology, Epidemiology , 2002 .

[29]  A. M. Arias Epithelial Mesenchymal Interactions in Cancer and Development , 2001, Cell.

[30]  D. Botstein,et al.  Variation in gene expression patterns in human gastric cancers. , 2003, Molecular biology of the cell.

[31]  T. Nagayo Tumours of the stomach. , 1973, IARC scientific publications.

[32]  G. Turashvili,et al.  Differentiation of tumours of ductal and lobular origin: II. Genomics of invasive ductal and lobular breast carcinomas. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[33]  T. Motoyama,et al.  COMPARISON OF SEVEN CELL LINES DERIVED FROM HUMAN GASTRIC CARCINOMAS , 1986, Acta pathologica japonica.

[34]  Izhak Haviv,et al.  Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. , 2003, Cancer research.

[35]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[36]  Y. Chung,et al.  Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. , 1995, British Journal of Cancer.

[37]  Sangsoo Kim,et al.  Meta- and gene set analysis of stomach cancer gene expression data. , 2007, Molecules and cells.

[38]  H. Yoo,et al.  Expression profiling and subtype-specific expression of stomach cancer. , 2003, Cancer research.

[39]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Ribeiro,et al.  Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma , 1981, Cancer.

[41]  M. Yashiro,et al.  Fibrosis in the peritoneum induced by Scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination , 1996, Cancer.

[42]  H. Thompson Morson and Dawson's gastrointestinal pathology , 1991 .

[43]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[44]  D. Day,et al.  Morson & Dawson's Gastrointestinal Pathology , 1990 .

[45]  M. Difalco,et al.  Regulator of differentiation 1 (ROD1) binds to the amphipathic C‐terminal peptide of thrombospondin‐4 and is involved in its mitogenic activity , 2009, Journal of cellular physiology.

[46]  Hanna Vauhkonen,et al.  Pathology and molecular biology of gastric cancer. , 2006, Best practice & research. Clinical gastroenterology.

[47]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[48]  M. Paulsson,et al.  Thrombospondin-4 Binds Specifically to Both Collagenous and Non-collagenous Extracellular Matrix Proteins via Its C-terminal Domains* , 2000, The Journal of Biological Chemistry.

[49]  P. Caroni,et al.  Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth , 1995, The Journal of cell biology.

[50]  G. Stemmermann,et al.  A survival study of intestinal and diffuse types of gastric carcinoma , 1974, Cancer.

[51]  Jan Komorowski,et al.  Gene expression based classification of gastric carcinoma. , 2004, Cancer letters.

[52]  D. Day,et al.  Epithelial Tumours of the Stomach , 2008 .

[53]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[54]  G. Turashvili,et al.  Differentiation of tumours of ductal and lobular origin: I. Proteomics of invasive ductal and lobular breast carcinomas. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[55]  S. Hundahl,et al.  The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy , 2000, Cancer.

[56]  J. Lawler,et al.  Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1. , 1994, Molecular biology of the cell.

[57]  B. Tilton,et al.  Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. , 2005, Molecular and cellular probes.

[58]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[59]  G. Sadvakassova,et al.  Osteopontin and the C-terminal peptide of thrombospondin-4 compete for CD44 binding and have opposite effects on CD133+ cell colony formation , 2009, BMC Research Notes.